Dr. Bailey is Interim Director of the University of Wisconsin Carbone Cancer Center and Professor of Medicine at the University of Wisconsin School of Medicine and Public Health. He is the principal investigator on most of the initial oral POH trials from the University of Wisconsin and has a research focus in anti-cancer drug development, especially chemoprevention. Dr. Bailey is the University’s expert on drug and nutrient development for the prevention or treatment of cancer and a national expert on chemoprevention.

Dr. Chamberlain is a Professor of Neurology at the University of Washington, Fred Hutchinson Cancer Research Center, and Seattle Cancer Care Alliance. He is a world-renowned neuro-oncologist who is known for his work on leptomeningeal carcinomatosis. Dr. Chamberlain developed many of the methods used today in evaluating and managing neoplastic meningitis and has increasingly focused on clinical trials for primary brain tumors

Dr. Gould is Professor of Medicine at the University of Wisconsin, and the investigator who initiated studies of POH as an anti-cancer agent. His laboratory is seeking the molecular basis that causes monoterpenes to selectively induce apoptosis and inhibit proliferation in cancer cells by investigating the effects of those drugs on cell cycle associated protein and signaling pathways.

Dr. Levin is President and R&D Director of Norac Pharma, and has helped in developing, manufacturing and testing POH formulations. He has extensive experience in pharmaceutical process R&D and manufacturing in Europe, Canada, the United States, and India, working with ICI, Zeneca, AstraZeneca, Avecia, Torcan, and Piramal Healthcare, prior to Norac Pharma.

Dr. Peereboom is a medical oncologist specializing in the management of brain tumors, with an active practice at the Cleveland Clinic. His specialty interests are in neuro-oncology and experimental therapeutics, and he’s a prominent member of the Society of Neuro-Oncology. Dr. Peereboom was involved in some of the initial oral POH studies.

Dr. Prados is Director of the Department of Translational Research at the University of California, San Francisco. He has over 20 years of experience at UCSF in treating and supervising the treatment of adults and children who have brain tumors. He also heads The National Cancer Institute’s Adult Brain Tumor Consortium, He is the principal investigator of the Pediatric Brain Tumor Consortium site at UCSF, which is developing effective new strategies for treating children with malignant brain tumors.

Dr. Davitz is both a medical doctor and a patent lawyer. Prior to starting his practice in patent law, Dr. Davitz was an assistant professor in pathology. He has been able to effectively combine his knowledge of medicine and law into a thriving patent law practice as a partner of Axinn,Veltrop. He is the key advisor for NTI’s patent strategy.

Dr. Wen is Director of Cancer Neurology at Brigham and Women’s Hospital, Director of Dana-Farber/Brigham and Women’s Cancer Center Neuro-Oncology Disease Center, and Professor of Neurology, Harvard Medical School. His research is focused on novel treatments of brain tumors, especially targeted molecular agents. Another of his clinical interests is neurologic complications of cancer.